Several other brokerages also recently commented on ITRM. Zacks Investment Research upgraded Iterum Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 17th. HC Wainwright reiterated a buy rating and set a $17.00 price target on shares of Iterum Therapeutics in a report on Thursday, August 15th. Finally, Royal Bank of Canada lowered their price target on Iterum Therapeutics to $17.00 and set an outperform rating on the stock in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Iterum Therapeutics has a consensus rating of Buy and an average target price of $15.75.
Shares of ITRM stock opened at $6.41 on Wednesday. Iterum Therapeutics has a 12 month low of $4.70 and a 12 month high of $11.22. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $6.65 and its two-hundred day moving average is $6.85.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
See Also: Why Dividend Stocks May Be Right for You
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.